Tango Therapeutics, Inc. (TNGX) NASDAQ
26.26
-0.68(-2.52%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
26.26
-0.68(-2.52%)
Currency In USD
Address
100 Binney Street
Boston, MA 02142
United States of America (the)
Phone
857 320 4900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
155
First IPO Date
September 03, 2020
| Name | Title | Pay | Year Born |
| Barbara L. Weber | President, Chief Executive Officer & Director | 1.13M | 1957 |
| Douglas J. Barry | Chief Compliance Officer & Corporate Secretary | 674,222 | 1970 |
| Daniella Beckman | Chief Financial Officer | 717,616 | 1979 |
| Adam S. Crystal | President of Research & Development | 882,167 | 1977 |
| Antoni Ribas | Founder & Member of Scientific Advisory Board | 0 | 1967 |
| William G. Kaelin Jr. | Founder & Member of Scientific Advisory Board | 0 | 1958 |
| Alan Ashworth | Founder & Member of Scientific Advisory Board | 0 | 1961 |
| Michael Palmieri | Chief Technical Operations Officer | 0 | N/A |
| Jannik N. Andersen | Chief Scientific Officer | 0 | N/A |
| Elizabeth Pingpank Hickin | Vice President of IR & Corporate Communications | 0 | N/A |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.